MedTrace Logo

Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors

NCT04587817 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2020-10-14

No results posted yet for this study

Summary

This trial will explore effectiveness and safety using the combination therapy of camrelizumab and hyperfractionated radiotherapy in patients with massive tumor including non-small cell lung cancer, soft tissue sarcoma or urothelial carcinoma. Hypofractionation which represented by stereotactic body radiation therapy (SBRT) is a technique that delivers higher daily doses of radiation over a shorter period of time. This trial will also observe the index which can influencing the curative effect of hyperfractionated radiotherapy combined with immunotherapy.

Conditions

  • Immunotherapy
  • SBRT
  • Bulky Tumor

Interventions

COMBINATION_PRODUCT

camrelizumab+hyperfractionated radiotherapy

Immunotherapy combined with hyperfractionated radiotherapy

Sponsors & Collaborators

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Xianshu Gao, MD,PhD · Peking University First Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-15
Primary Completion
2022-09-19
Completion
2023-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04587817 on ClinicalTrials.gov